ASGARD Advises Avadim Health, Inc. on $60 Million Financing
Published: Oct 10, 2018
NEW YORK, /PRNewswire/ -- ASGARD Partners & Co. ("ASGARD"), a leading middle-market investment and advisory firm, is pleased to announce today that it has acted as exclusive advisor to Avadim Health, Inc. ("Avadim Health"), the Bionome Therapies™ life sciences company, on its $40 million debt financing round with an additional accordion facility of up to $20 million. Hayfin Capital Management was the sole investor in the financing.
Steve Woody, Chairman and CEO of Avadim Health, stated, "The financing represents the accomplishment of a major milestone in our overall capitalization plan. We are pleased to partner with Hayfin and their investment experience in our industry. Hayfin's investment will allow us to continue to drive execution and support the company's strong growth trajectory. We would also like to thank ASGARD for their relentless support in helping us manage the process to close this transaction. ASGARD's strong understanding of the life sciences sector and its ability to help navigate structuring and financial challenges resulted in a great outcome for all parties."
"We are proud to have been able to help Avadim Health as it continues to build a world-class company and a fantastic brand in the healthcare and consumer spaces with their family of products. With this financing, we are excited to see the Company continue to grow and be in a position to serve even more customers and improve their lives. Working with Steve and the rest of his team has been a real privilege," said Nicholas Desjardins, Partner at ASGARD.
About Avadim Health, Inc.:
View original content to download multimedia:http://www.prnewswire.com/news-releases/asgard-advises-avadim-health-inc-on-60-million-financing-300728658.html
SOURCE ASGARD Partners & Co.